AmeReGen-ImmunoCure

AmeReGen-ImmunoCure is a biotechnology company specializing in regenerative medicine and immunotherapy, specifically the development of Cellular Intravascular Targeting Agents (CITA). The company utilizes a proprietary robotic manufacturing process to produce adult stem cell products designed to treat advanced and multi-drug-resistant cancers. Founded and led by Dr. Ernest G. Hope, AmeReGen-ImmunoCure focuses on "re-embryonalized" adult differentiated cells that provide graft-versus-tumor effects without the toxicity of conventional treatments. While the company has claimed clinical use and regulatory acceptance in parts of Europe, its technologies have not received widespread adoption or FDA approval in the United States.